https://doi.org/10.4081/reumatismo.2020.1267

Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life

Vol. 72 No. 2 (2020)
Submitted: 3 December 2019
Accepted: 15 April 2020
Published: 23 July 2020
Risk of fracture, anti-osteoporotic medications
Abstract Views: 1466
PDF: 1040
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

G. Adami
adami.g@yahoo.com
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
A. Giollo
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
M. Rossini
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
G. Orsolini
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
C. Benini
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
O. Viapiana
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
D. Gatti
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.
A. Fassio
Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona, Italy.

In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Adami, G., Giollo, A., Rossini, M., Orsolini, G., Benini, C., Viapiana, O., … Fassio, A. (2020). Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo, 72(2), 71–74. https://doi.org/10.4081/reumatismo.2020.1267

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.